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Abbreviations 
D-MELD Donor age × MELD score 
ESLD  End-stage liver disease 
MELD  Model of end-stage liver disease 
ReLT-KT Simultaneous liver retransplantation and kidney transplantation 
SLKT  Simultaneous liver and kidney transplantation 
UCLA  University of California Los Angeles 
UNOS  United Network of Organ Sharing
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Simultaneous liver and kidney transplantation (SLKT) is an increasingly performed 
procedure in patients with end-stage liver disease (ESLD) and renal failure.1 According to a 
recent report, more than 700 SLKT were performed in the United States in 2016 representing 
9.3% of all annual liver transplants.2 This proportion has been continuously growing during 
the past decade and accounted for 2% only in the year 2000. In adult SLKT, chronic renal 
disease and sustained acute kidney injury are the 2 dominant causes of renal failure. In 
critically ill liver transplant candidates with underlying chronic kidney disease, renal failure 
might be often driven by acute-on-chronic conditions.  
Cauchy and colleagues reported on a unique cohort of patients undergoing 
simultaneous liver retransplantation and kidney transplantation (ReLT-KT).3 Although 
several studies reported outcomes of SLKT, none of those focused exclusively on the 
scenario of liver retransplantation. The authors of 2 French liver transplant units analyzed the 
outcome of 45 recipients who underwent ReLT-KT during the period from 1994 to 2012. In 
parallel to the trends of growing SLKT procedures in the United States, the French study 
observed similar increased rates of ReLT-KT over time. In this study, the most common 
indications for liver retransplantation were recurrent liver disease and cholangitis, while 
chronic renal failure due to calcineurin inhibitor toxicity was the leading indication for 
simultaneous kidney transplantation. Although the authors differentiated between 4 clinical 
scenarios, the decision making for ReLT-KT was done on a case-by-case basis and did not 
rely on established guidelines for simultaneous kidney transplantation. This fact highlights 
the long lasting problem of lacking established criteria when to proceed with simultaneous 
kidney transplantation.4 Even in the United States, there were no formal criteria for SLKT 
before August 2017 and centers had to request simultaneous kidney transplantation according 
to their need and clinical judgement. Meanwhile, UNOS and other nonprofit transplant 
organizations have recently implemented eligibility criteria for SLKT.2 However, we have to 
AC
CE
PT
ED
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
4 
 
keep in mind that the study period of the French cohort closed in 2012 when worldwide no 
formal criteria for SLKT existed. Therefore, there is an urgent need for outcome research of 
contemporary SLKT cohorts, which follow implemented eligibility criteria for additional 
kidney transplantation in primary liver transplantation or retransplantation settings. 
 The central finding of the French study was the high early mortality rate of 27% 
among recipients undergoing ReLT-KT.3 The authors identified D-MELD (donor age × 
MELD score) as only independent factor associated with overall survival. This finding 
indicates that donor age and MELD score significantly determine early outcome after ReLT-
KT. Under this perspective, donor age might represent a certain surrogate marker for donor 
organ quality for both liver and kidney while MELD score reflects the hepatic and renal 
medical acuity of the recipient. In other words, critically ill recipients undergoing ReLT-KT 
with organs from donors with advanced age do poorly and have a high risk to experience 
futile outcome. Probably everybody would agree with the authors that this finding has 
important clinical implications for appropriate selection of ReLT-KT candidates. The pattern 
of risk factors of the French study adds to the findings of a recently published study from the 
University of California Los Angeles (UCLA) in an even sicker recipient population.5 In this 
study, 145 patients underwent SLKT of whom 35 had ReLT-KT with a median MELD score 
of 35 compared to a MELD score of 23 in the French study. However, both studies differed 
significantly in their composition of underlying causes for end-stage renal disease. The study 
by Cauchy and colleagues had an almost-zero rate of acute kidney injury (2% versus 43%) 
but an overwhelming rate of chronic kidney disease (98 versus 57%) compared to the study 
from UCLA. Regardless of these differences, retransplantation, MELD score, and kidney 
donor risk index with age as component variable were independently associated with renal 
allograft futility and mirrored in some extent the risk profile of the French study. However, 
we have to keep in mind that early mortality is not only an unfortunate event for the recipient 
CC
EP
TE
D
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
5 
 
but it also implies a loss of 2 donor organs with significant impact on patients on the liver and 
kidney waiting list.6 Therefore, the study significantly contributes to the important body of 
evidence that elucidates the question of whether to proceed or defer simultaneous kidney 
transplantation or even ReLT-KT. 
Interestingly, the subgroup analysis of the French study revealed that the highest 90-
day mortality of approximately 50% was observed in patients with dominant and/or severe 
liver impairment while recipients with dominant kidney and/or moderate liver impairment 
had zero mortality.3 The authors argue that these findings imply that ReLT-KT needs to be 
considered earlier before severe liver impairment occurs (Figure 1) and that high acuity 
recipients should receive optimal organs. Although these scenarios are desirable, reality is 
often different especially for transplant centers facing extreme recipients (MELD 35+). 
Therefore, delayed or deferred kidney transplantation after liver transplantation might be a 
reasonable option in very sick recipients requiring ReLT-KT. The principle behind this 
strategy is to avoid simultaneous kidney implantation in a hostile and unstable environment 
when renal allograft futility is likely. In a recent study, 63 of 130 combined liver and kidney 
transplantation had delayed kidney implantation by average of 50 hours of cold ischemia 
while maintained on machine perfusion.7 The authors of this study reported improved 
survival for patients undergoing delayed versus simultaneous kidney transplantation. If 
delayed kidney implantation is not an option due to prolonged critical illness after liver 
transplantation, deferred kidney transplantation might be the preferred strategy after hepatic 
allograft engraftment occurred. However, this strategy requires allocation rules where kidney 
allocation is furthermore prioritized in a scenario of kidney-after-liver transplantation. 
Regardless of delayed or deferred kidney transplantation, both strategies follow the principle 
of best donor organ utilization (Figure 1). 
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Although SLKT offers an unquestionable survival benefit for many patients with 
ESLD and simultaneous chronic kidney disease and/or acute kidney injury, the study by the 
French group highlights the importance of appropriate selection and management of patients 
undergoing ReLT-KT or SLKT. Future research priorities should focus on contemporary 
SLKT studies incorporating both renal indications of chronic kidney disease and acute kidney 
injury in order to identify the highest risk patients and to avoid futile SLKT and ReLT-KT. 
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Figure legend 
Figure 1: Strategies to avoid futile outcome in combined liver and kidney transplantation. 
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Figure 1 
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